Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: A propensity matched study of 1,790 patients
American Journal of Hematology | November 4, 2016 | Volume: 92 | Issue: 2 | Pages: No page available
10.1002/ajh.24599
| PMID 27813147